<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4344C8DA-9733-4D32-B29D-ED27B4EE73D8"><gtr:id>4344C8DA-9733-4D32-B29D-ED27B4EE73D8</gtr:id><gtr:name>Joint Clinical Research Center, Kampala</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/FDEC91A0-8557-4ECC-9E72-E3402494D6DB"><gtr:id>FDEC91A0-8557-4ECC-9E72-E3402494D6DB</gtr:id><gtr:name>University of Zambia</gtr:name><gtr:address><gtr:line1>PO Box 50697</gtr:line1><gtr:line2>Ridge Way Campus</gtr:line2><gtr:line4>Lusaka</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Zambia</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/93F65D4D-5E08-4949-92D6-65EC36F1E83F"><gtr:id>93F65D4D-5E08-4949-92D6-65EC36F1E83F</gtr:id><gtr:name>University of Zimbabwe</gtr:name><gtr:address><gtr:line1>PO Box MP 167</gtr:line1><gtr:line2>Mount Pleasant</gtr:line2><gtr:line4>Harare</gtr:line4><gtr:line5>Zimbabwe</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Zimbabwe</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/FC20619C-24CC-4562-8F2A-B1C34FB19874"><gtr:id>FC20619C-24CC-4562-8F2A-B1C34FB19874</gtr:id><gtr:name>University Medical Centre Nijmegen</gtr:name><gtr:address><gtr:line1>Uinversity Medical Centre Nijmegen</gtr:line1><gtr:line2>PO Box 9101</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A6E6C042-46F9-434B-970F-5F9C8BCF6F1A"><gtr:id>A6E6C042-46F9-434B-970F-5F9C8BCF6F1A</gtr:id><gtr:name>PENTA Foundation</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/41A6F529-3374-4F2A-8350-29C571A8C235"><gtr:id>41A6F529-3374-4F2A-8350-29C571A8C235</gtr:id><gtr:name>European Commission (EC)</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4344C8DA-9733-4D32-B29D-ED27B4EE73D8"><gtr:id>4344C8DA-9733-4D32-B29D-ED27B4EE73D8</gtr:id><gtr:name>Joint Clinical Research Center, Kampala</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/FDEC91A0-8557-4ECC-9E72-E3402494D6DB"><gtr:id>FDEC91A0-8557-4ECC-9E72-E3402494D6DB</gtr:id><gtr:name>University of Zambia</gtr:name><gtr:address><gtr:line1>PO Box 50697</gtr:line1><gtr:line2>Ridge Way Campus</gtr:line2><gtr:line4>Lusaka</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Zambia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/93F65D4D-5E08-4949-92D6-65EC36F1E83F"><gtr:id>93F65D4D-5E08-4949-92D6-65EC36F1E83F</gtr:id><gtr:name>University of Zimbabwe</gtr:name><gtr:address><gtr:line1>PO Box MP 167</gtr:line1><gtr:line2>Mount Pleasant</gtr:line2><gtr:line4>Harare</gtr:line4><gtr:line5>Zimbabwe</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Zimbabwe</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/FC20619C-24CC-4562-8F2A-B1C34FB19874"><gtr:id>FC20619C-24CC-4562-8F2A-B1C34FB19874</gtr:id><gtr:name>University Medical Centre Nijmegen</gtr:name><gtr:address><gtr:line1>Uinversity Medical Centre Nijmegen</gtr:line1><gtr:line2>PO Box 9101</gtr:line2><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A6E6C042-46F9-434B-970F-5F9C8BCF6F1A"><gtr:id>A6E6C042-46F9-434B-970F-5F9C8BCF6F1A</gtr:id><gtr:name>PENTA Foundation</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/41A6F529-3374-4F2A-8350-29C571A8C235"><gtr:id>41A6F529-3374-4F2A-8350-29C571A8C235</gtr:id><gtr:name>European Commission (EC)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E7EC8F72-BE65-417D-BEFB-F4B23DD7A691"><gtr:id>E7EC8F72-BE65-417D-BEFB-F4B23DD7A691</gtr:id><gtr:firstName>Elizabeth</gtr:firstName><gtr:otherNames>G</gtr:otherNames><gtr:surname>Lyall</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/4CFEE661-9281-4E12-B253-109123EF97A4"><gtr:id>4CFEE661-9281-4E12-B253-109123EF97A4</gtr:id><gtr:firstName>Ann</gtr:firstName><gtr:otherNames>Sarah</gtr:otherNames><gtr:surname>Walker</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/ADB3E928-199A-4F20-A7FF-C44CA9F3AC23"><gtr:id>ADB3E928-199A-4F20-A7FF-C44CA9F3AC23</gtr:id><gtr:firstName>Vas</gtr:firstName><gtr:surname>Novelli</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9B748D8A-15E4-445B-A89A-C3F68BBFA86F"><gtr:id>9B748D8A-15E4-445B-A89A-C3F68BBFA86F</gtr:id><gtr:firstName>Mike</gtr:firstName><gtr:surname>Sharland</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/58B69503-B9E3-43E3-AEB2-82D521E4C95E"><gtr:id>58B69503-B9E3-43E3-AEB2-82D521E4C95E</gtr:id><gtr:firstName>Diana</gtr:firstName><gtr:surname>Gibb</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FEBF5F34-3603-436C-BC7D-21B93EC7A0C6"><gtr:id>FEBF5F34-3603-436C-BC7D-21B93EC7A0C6</gtr:id><gtr:firstName>Nigel</gtr:firstName><gtr:otherNames>Jonathan</gtr:otherNames><gtr:surname>Klein</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/B7355D50-F853-4F11-8846-876C4D6E3044"><gtr:id>B7355D50-F853-4F11-8846-876C4D6E3044</gtr:id><gtr:firstName>Andrew</gtr:firstName><gtr:surname>Riordan</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/ADA12B3F-11EC-4D2A-9B49-C28BFB8D68B2"><gtr:id>ADA12B3F-11EC-4D2A-9B49-C28BFB8D68B2</gtr:id><gtr:firstName>Gareth</gtr:firstName><gtr:surname>Tudor-Williams</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0400858"><gtr:id>702EBD8C-E7BD-4B63-9E03-6C46C9962EFC</gtr:id><gtr:title>Support for UK clinical centres enrolling in PENTA trials</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400858</gtr:grantReference><gtr:abstractText>Combinations of anti-HIV drugs (antiretroviral therapy or ART) can slow the growth of the HIV virus in the body, and now children with HIV can often live into adulthood. However, there are problems with taking these drugs long-term; in terms of both side effects and being able to take them regularly as required. We need to understand how best to use the ART drugs we have, by looking at whether it is possible to stop taking them at certain times, as well as ensuring that we are giving children the correct doses. However we also need to explore new ways of treating those children who do not respond as well to these drugs - for example, by encouraging the body to fight HIV itself, rather than using drugs to kill the virus. 

Randomised clinical trials where neither the family nor the doctor choose the treatment are the best way of evaluating treatment strategies. The current proposal is for 3 clinical trials in children:

 i. Some ongoing trials are exploring whether it is safe for adults to stop therapy for a while if they have very low amount of virus in the blood (HIV viral load) and good CD4 counts (which indicate how well the body can fight infections). It is important to assess this strategy in children as well, because their immune system is still developing and may be better at repairing itself. Otherwise they will have to take drugs for life from a young age.
 ii. In adults an experimental medicine called IL-2, given as an injection, can increase the CD4 count. However, IL-2 may work much better in children, again because their immune system is still developing and responds better to help. We also need to understand whether children can tolerate the injections and side effects.
 iii. One reason for medicines working less well in children than in adults is that it is difficult to get the doses right at different ages, weights and heights, and with individual children?s metabolisms. Directly measuring the level of drug in the blood and then altering the dose to get the best blood levels might be better at lowering the HIV viral load and might also reduce side effects. 

Results from all these trials will be promoted at national and international conferences, the PENTA website (www.pentatrials.org), treatment guidelines, and newsletters to ensure that families and doctors have access to them.</gtr:abstractText><gtr:technicalSummary>PENTA is a European collaboration, conducting clinical trials addressing questions relevant to the care and treatment of HIV-infected children, where results cannot be extrapolated from trials in adults. Trials are funded from several sources, mainly the EU and governmental bodies with some support from the pharmaceutical industry. The MRC Clinical Trials Unit, with INSERM SC10 in Paris, co-ordinates the trials on behalf of PENTA. Core MRC support for PENTA consists of 0.5 Band 5 data manager, and the pivotal involvement of CTU scientists in the Steering Committee as well as the operational and statistical aspects of the trials.

This Research Grant would support UK enrolment into 3 new PENTA trials in children with chronic HIV infection. 

PENTA 11 is a randomised open parallel group trial to evaluate the safety of planned treatment interruptions, as a strategy for reducing life-time exposure to therapy whilst avoiding increased risk of disease progression. 100 children who have responded well to therapy will be randomised to continue their current treatment or interrupt treatment until their CD4% falls below a threshold, and followed for 72 weeks. An estimated 25-30 children will be enrolled in the UK.

PENTA 10, a collaboration with the USA PACTG, is a randomised open-label parallel group trial to evaluate the safety and efficacy of adding subcutaneous Interleukin-2 (IL-2) to effective antiretroviral therapy, as an immune-based strategy for improving host control of HIV. 40 children who have not responded well immunologically to therapy will be randomised to immediate cycles of IL-2 or IL-2 deferred for 48 weeks, and followed for 96 weeks. This trial will include intensive immunological and virological assessments. An estimated 4-6 children will be enrolled in the UK. 

PENTA 14 is a randomised open parallel group trial to evaluate the use of therapeutic drug monitoring (TDM), as a strategy to improve virological suppression and adherence and reduce toxicity, by avoiding under- and over-dosing. 166 children starting a new antiretroviral regimen will be randomised to full TDM (a 5-point pharmacokinetic curve), single sample TDM or no TDM, and followed for 96 weeks. It is estimated that 20-40 children will be enrolled in the UK. 

Funding is requested to support the research activity in clinical sites in the UK: ie doctor and nurse time in completing CRFs; blood sampling, separation, storage and transport; hospital admissions and laboratory work not contributing to individual patient management (non-reclaimable from NHS service support).</gtr:technicalSummary><gtr:fund><gtr:end>2008-06-30</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>67642</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Radboud University Nijmegen Medical Center</gtr:collaboratingOrganisation><gtr:country>Netherlands, Kingdom of the</gtr:country><gtr:description>Radboud University Nijmegen Medical Centre, the Netherlands</gtr:description><gtr:id>8C0387E4-F5C1-4EDA-9C41-72B5966DDA64</gtr:id><gtr:impact>Radbound University has been involved in the analysis and writing up of the pharmacokinetics data from ARROW, PENTA 18 and the CHAPAS trials which has resulted in presentations at international conferences, peer review publications, FDA and EMA approval of drugs and Clinton Foundation and UNITAID dissemination in Africa.</gtr:impact><gtr:partnerContribution>Long standing nesting of key pharmacokinetic studies within larger trial programmes. Contributed to several PhD studentships (all Dutch), PK data resulted in licensing of new appropriate antiretroviral formulations for children in resource limited settings.</gtr:partnerContribution><gtr:piContribution>The research team at the MRC co-ordinates the ARROW, CHAPAS-1,2,3 and PENTA trials and provides scientific input and analysis of EDCTP funded VITA 1 and 2 trials.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Joint Clinical Research Center, Kampala</gtr:collaboratingOrganisation><gtr:country>Uganda, Republic of</gtr:country><gtr:description>Joint Clinical Research Centre, Kampala, Uganda</gtr:description><gtr:id>6D24467B-B1F5-4CFE-90F1-37BD8C02AE22</gtr:id><gtr:impact>Trial results and substudies DART, ARROW, CHAPAS 3, including economic substudies
DART trial Fim
Young lives project from ARROW trial
Outputs from the Lablite Project</gtr:impact><gtr:partnerContribution>Clinical trials site and coordination of satelite sites. Laboratory substudies e.g HIV virology and immunology</gtr:partnerContribution><gtr:piContribution>Multicentre clinical trial collaboration on DART, ARROW, CHAPAS 3, PENTA 16 (BREATHER) and REALITY Trials and substudies
Partner on the Lablite Project and on PENTA 17 (SMILE) and PENTA 20 (ODYSSEY) trials</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>PENTA Foundation</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>PENTA Foundation</gtr:description><gtr:id>CE6E017E-00BB-44D2-9AC4-4FF80387AE1B</gtr:id><gtr:impact>completion and publication of PENTA 11, 15 and PENTA 18 trials; completion of main and extended follow-up PENTA 16 trial; finalisation of PENTA 17 protocol; activation and co-ordination of PENTA 20</gtr:impact><gtr:partnerContribution>INSERM, France and PHPT, Thailand clinical trials units work collaboratively with MRC CTU at UCL on coordination of PENTA trials.</gtr:partnerContribution><gtr:piContribution>Scientific lead in writing project proposal. scientific leadership, coordination of trials and studies, coordinating role and speakers on PENTA training online and residential courses worldwide. Contribute to European PENTA guidelines.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Zambia</gtr:collaboratingOrganisation><gtr:country>Zambia, Republic of</gtr:country><gtr:description>University of Zambia</gtr:description><gtr:id>8D5B0349-B4F8-4081-B920-D215D0F850E7</gtr:id><gtr:impact>Trial results and substudies and implementation and impact of CHAP &amp;amp; CHAPAS 1 and 3 trials, including economic analyses
CHAPAS 3 trial just completed and papers ongoing</gtr:impact><gtr:partnerContribution>enrolled patients into CHAP, CHAPAS 1 &amp;amp; 3 trials
Project lead of EDCTP project
Contribution to all aspects of reserach including outputs and implementation (CHAP Trial of cotimroxazole prophylaxis)</gtr:partnerContribution><gtr:piContribution>Contribution to CHAP, CHAPAS 1 &amp;amp; 3 trials</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Zimbabwe</gtr:collaboratingOrganisation><gtr:country>Zimbabwe, Republic of</gtr:country><gtr:description>University of Zimbabwe</gtr:description><gtr:id>89286E4A-E063-485E-961D-4A446EE53E22</gtr:id><gtr:impact>DART and ARROW trials and substudy outcomes and implementation impact; 
ARROW young lives study and economic substudies
REALITY trial ongoing
LAblite Project outputs</gtr:impact><gtr:partnerContribution>Clinical sites for DART, ARROW, REALITY, PENTA 20(ODYSSEY) Trials
Staff are partners in all aspects of reserach from design through to enrolling patients and writing results papers</gtr:partnerContribution><gtr:piContribution>DART, ARROW, REALITY Trials funding and coordination by MRC CTU
LAblite Project on enabling rollout of antiretroviral therapy.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>European Commission (EC)</gtr:collaboratingOrganisation><gtr:country>European Union (EU)</gtr:country><gtr:description>EuroCoord</gtr:description><gtr:id>7561F6D6-F578-42CD-9A86-3B0F9FE2C1A4</gtr:id><gtr:impact>The PENPACT-1 (PENTA 9 / PACTG 390) Study Team. First-line antiretroviral therapy initiation with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor combination and switch at higher versus low viral load in HIV-infected children: an open randomised controlled phase 2/3 trial. Lancet Infectious Diseases. April: 2011, 273-283.</gtr:impact><gtr:partnerContribution>scientific coordinator 2011-2012 (Work Package 3). data harmonisation</gtr:partnerContribution><gtr:piContribution>scientific lead in writing project proposal; major partner. running paediatric PENTA trials and coordinating EPPICC (European Pregnancy and Paediatric HIV Cohort Collaboration).</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Talk to HIV infected young people</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AB79108E-AD3A-4707-ACD2-2B5CCF710DE1</gtr:id><gtr:impact>40 young people with HIV infection attended a session on involvement in clinical trials

This led to further discussion with the CHIVA youth group about consumer involvement in trials</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2009,2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Website</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:id>1A494CA8-C467-43DE-888D-D135858026A4</gtr:id><gtr:impact>PENTA trials website is regularly updated with information about the PENTA trials and activities

Queries are received from healthcare workers and from students about trials and HIV in general</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Health professionals</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Tr@inforPed HIV Training Course</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>F00FB15B-050A-4EBD-A630-4BEE4FFEB767</gtr:id><gtr:impact>Tr@inforPed HIV has been a highly successful training course run by experts from the PENTA network since 2005. The course is designed for all healthcare professionals caring for children living with HIV, including training doctors, nurses, counsellors and psychologists. In 2008 the course became part of the Oxford Paediatric Infectious Diseases Diploma.</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>PENTA Guidelines for the use of antiretroviral therapy</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>37A2A71F-4A0B-41F1-BC8E-28C4B067E2CF</gtr:id><gtr:impact>PENTA guidelines for the use of antiretroviral therapy are regularly updated (latest version 2009) and are used in developed countries worldwide.</gtr:impact><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Currently being analysed
Kaletra 100/25ml paediatric tablets once daily in the KONCERT (PENTA 18) in process of submission to FDA</gtr:description><gtr:id>1F87897C-3A76-4E25-8013-EFBB731AF8D5</gtr:id><gtr:impact>If lopinavir is shown to be non-inferior when taken once daily rather than twice daily in terms of virological suppression, we expect this will become the standard of care for this drug.</gtr:impact><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>PENTA 18 - Once daily Kaletra 100/25ml</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>ISRCTN02452400</gtr:ukcrnIsctnId><gtr:url>http://www.pentatrials.org</gtr:url><gtr:yearDevCompleted>2009</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>All young people enrolled in this clinical trial evaluating the role of Short Cycle Therapy (5 days on, 2 days off) in the management of HIV infection will be followed until July 2014. Young people continued to be followed on their randomised treatment, where appropriate, in a 2 year extended follow-up period until July 2016. Results were presented at CROI 2017</gtr:description><gtr:id>84A9BCAF-44F2-4E54-9790-15CF87FDE174</gtr:id><gtr:impact>Results were presented at CROI 2017. A further trial is planned to look at the possibility of a short course therapy in settings where viral loads are measured annually.</gtr:impact><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>BREATHER - PENTA 16</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>ISRCTN97755073</gtr:ukcrnIsctnId><gtr:url>http://pentatrials.org</gtr:url><gtr:yearDevCompleted>2010</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Data from PENTA 13 and PENTA 15 are being submitted to the FDA and EMA to support once daily dosing of abacavir and lamivudine in children with HIV infection.</gtr:description><gtr:id>E926061E-F00D-4338-85DD-331FF0BB0AEE</gtr:id><gtr:impact>Data from PENTA 15 (and PENTA 13) are being submitted to regulatory bodies to support a marketing authorisation of once daily dosing.</gtr:impact><gtr:stage>Market authorisation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>PENTA 15</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>ISRCTN38147516</gtr:ukcrnIsctnId><gtr:url>http://www.pentatrials.org</gtr:url></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>5 year follow-up is continuing of children enrolled in PENTA 11 - a randomised study to evaluate CD4 driven planned treatment interruptions in children with HIV infection.</gtr:description><gtr:id>7E11DB17-9A06-404C-BDF5-2F00946030CF</gtr:id><gtr:impact>PENTA 11 and the CHER trial have provided randomised data for the possibility of planned treatment interruptions in HIV treatment.</gtr:impact><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>PENTA 11 - TICCH</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>ISRCTN36694210</gtr:ukcrnIsctnId><gtr:url>http://pentatrials.org</gtr:url></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>A randomised study of combination antiretroviral regimens and treatment-switching strategies in antiretroviral naive children &amp;gt; 30 days and &amp;lt; 18 years of age</gtr:description><gtr:id>0FB6D347-D4A6-4829-92C7-ED30B2D03842</gtr:id><gtr:impact>WHO guidelines have been updated to include use of an NNRTI in children &amp;gt; 3 years of age and in children less than 3 years as an alternative to Kaletra based on trial data which supports continuing treatment with an NNRTI as there is little difference in the resistance acquired on Pi or NNRTI.</gtr:impact><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Closed</gtr:status><gtr:title>PENPACT 1 - PENTA 9</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:ukcrnIsctnId>ISRCTN73318385</gtr:ukcrnIsctnId><gtr:url>http://www.pentatrials.org</gtr:url></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Data collected for the ongoing trials</gtr:description><gtr:id>FFD0D818-6797-489C-97E6-729F6815A45D</gtr:id><gtr:impact>Data used in meta-analyses and in modelling</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PENTA trials  database</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type><gtr:yearFirstProvided>2008</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E57389A7-37F5-4FF4-83C1-3396F7472D7A"><gtr:id>E57389A7-37F5-4FF4-83C1-3396F7472D7A</gtr:id><gtr:title>Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/68a3b528ff9b1f0d0bddbdf896177d53"><gtr:id>68a3b528ff9b1f0d0bddbdf896177d53</gtr:id><gtr:otherNames>Green H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/99AA8DE2-5015-48F6-9BF2-7A96A302B9F7"><gtr:id>99AA8DE2-5015-48F6-9BF2-7A96A302B9F7</gtr:id><gtr:title>Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children.</gtr:title><gtr:parentPublicationTitle>AIDS and behavior</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c3583e3b7afc8611b8cd7c4a38660e23"><gtr:id>c3583e3b7afc8611b8cd7c4a38660e23</gtr:id><gtr:otherNames>Harrison L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1090-7165</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C33C8216-203C-4DD0-904D-65C4D3FBC4E6"><gtr:id>C33C8216-203C-4DD0-904D-65C4D3FBC4E6</gtr:id><gtr:title>First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1791aadc4cb06cc1063b8502e9be8d52"><gtr:id>1791aadc4cb06cc1063b8502e9be8d52</gtr:id><gtr:otherNames>PENPACT-1 (PENTA 9/PACTG 390) Study Team</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/4064EF6C-7A1D-4A5A-AD70-FFA5347D9B14"><gtr:id>4064EF6C-7A1D-4A5A-AD70-FFA5347D9B14</gtr:id><gtr:title>Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/807907210ceade90d704265bbc5bc924"><gtr:id>807907210ceade90d704265bbc5bc924</gtr:id><gtr:otherNames>Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A65DE8F7-7A35-4D62-B022-3055DB82B457"><gtr:id>A65DE8F7-7A35-4D62-B022-3055DB82B457</gtr:id><gtr:title>Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-&amp;lt;36 months.</gtr:title><gtr:parentPublicationTitle>Antiviral therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/234e2513ef544c45cf1696b44305e1d5"><gtr:id>234e2513ef544c45cf1696b44305e1d5</gtr:id><gtr:otherNames>Paediatric European Network for Treatment of AIDS (PENTA)</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1359-6535</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/E4BB35EC-714D-4BD6-91EA-BA74835167C7"><gtr:id>E4BB35EC-714D-4BD6-91EA-BA74835167C7</gtr:id><gtr:title>PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection.</gtr:title><gtr:parentPublicationTitle>HIV medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/64a8f9ddfe566b451aae8c2e56d8388e"><gtr:id>64a8f9ddfe566b451aae8c2e56d8388e</gtr:id><gtr:otherNames>PENTA Steering Committee</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/D9F38250-CD21-4C8C-B392-74EDC7BC9C61"><gtr:id>D9F38250-CD21-4C8C-B392-74EDC7BC9C61</gtr:id><gtr:title>The immunological and virological consequences of planned treatment interruptions in children with HIV infection.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ce7d22f3749fc0e74eb321a4edccf869"><gtr:id>ce7d22f3749fc0e74eb321a4edccf869</gtr:id><gtr:otherNames>Klein N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/ED1B7E23-AAEB-42A2-B1D8-2B4A4322302F"><gtr:id>ED1B7E23-AAEB-42A2-B1D8-2B4A4322302F</gtr:id><gtr:title>Current CD4 cell count and the short-term risk of AIDS and death before the availability of effective antiretroviral therapy in HIV-infected children and adults.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/619570981e5c1fd56fbbfd0fa3f49528"><gtr:id>619570981e5c1fd56fbbfd0fa3f49528</gtr:id><gtr:otherNames>Dunn D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/5EF79E7F-DA97-450E-9F21-4EE3C6A7EE8F"><gtr:id>5EF79E7F-DA97-450E-9F21-4EE3C6A7EE8F</gtr:id><gtr:title>Lopinavir dosing in HIV-infected children in the United Kingdom and Ireland.</gtr:title><gtr:parentPublicationTitle>The Pediatric infectious disease journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/580ed1e27f7e81405129653e15eed505"><gtr:id>580ed1e27f7e81405129653e15eed505</gtr:id><gtr:otherNames>Donegan K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0891-3668</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/061525F3-95E0-4A75-9054-B008882524F4"><gtr:id>061525F3-95E0-4A75-9054-B008882524F4</gtr:id><gtr:title>Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children.</gtr:title><gtr:parentPublicationTitle>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/a0dbecd17f4f7bd82362b29113db110c"><gtr:id>a0dbecd17f4f7bd82362b29113db110c</gtr:id><gtr:otherNames>Cressey TR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>1058-4838</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/36BA2832-1926-4D65-9AD3-C2926D161357"><gtr:id>36BA2832-1926-4D65-9AD3-C2926D161357</gtr:id><gtr:title>Response to planned treatment interruptions in HIV infection varies across childhood.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/ce5a8111285d3bc63e05d5af42ae10be"><gtr:id>ce5a8111285d3bc63e05d5af42ae10be</gtr:id><gtr:otherNames>Paediatric European Network for Treatment of AIDS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400858</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>